Fig. 1From: Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burdenFlowchart of the study. NSCLC non-small cell lung cancer, AIS adenocarcinoma in situ, SNV single nucleotide variants. * In one sample molecular sequencing analysis was already performed in the context of the TSO500 validation trial written by Leonie Kroeze et al. [23]Back to article page